NO20004818L - Stabile doseringsformer av fluoxetin og dets enantiomere - Google Patents

Stabile doseringsformer av fluoxetin og dets enantiomere

Info

Publication number
NO20004818L
NO20004818L NO20004818A NO20004818A NO20004818L NO 20004818 L NO20004818 L NO 20004818L NO 20004818 A NO20004818 A NO 20004818A NO 20004818 A NO20004818 A NO 20004818A NO 20004818 L NO20004818 L NO 20004818L
Authority
NO
Norway
Prior art keywords
fluoxetine
enantiomers
dosage forms
stable dosage
stable
Prior art date
Application number
NO20004818A
Other languages
English (en)
Other versions
NO20004818D0 (no
Inventor
Martin P Redmon
Hal T Butler
Stephen A Wald
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Publication of NO20004818D0 publication Critical patent/NO20004818D0/no
Publication of NO20004818L publication Critical patent/NO20004818L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Kjemisk og fysikalsk stabile farmasøytiske formuleringer av det potente amidepressive fluoxetin, dets enantiomerer og salter.
NO20004818A 1998-03-27 2000-09-26 Stabile doseringsformer av fluoxetin og dets enantiomere NO20004818L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/049,227 US20030013740A1 (en) 1998-03-27 1998-03-27 Stable dosage forms of fluoxetine and its enantiomers
PCT/US1999/006601 WO1999049857A1 (en) 1998-03-27 1999-03-25 Stable dosage forms of fluoxetine and its enantiomers

Publications (2)

Publication Number Publication Date
NO20004818D0 NO20004818D0 (no) 2000-09-26
NO20004818L true NO20004818L (no) 2000-11-23

Family

ID=21958714

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20004818A NO20004818L (no) 1998-03-27 2000-09-26 Stabile doseringsformer av fluoxetin og dets enantiomere

Country Status (11)

Country Link
US (1) US20030013740A1 (no)
EP (1) EP1067918A1 (no)
JP (1) JP2002509882A (no)
KR (1) KR20010034703A (no)
CN (1) CN1303280A (no)
AU (1) AU3205399A (no)
BR (1) BR9909118A (no)
CA (1) CA2325858A1 (no)
NO (1) NO20004818L (no)
WO (1) WO1999049857A1 (no)
ZA (1) ZA200005189B (no)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372919B1 (en) * 2001-01-11 2002-04-16 Dov Pharmaceutical, Inc. (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as an anti-depressant agent
US6316672B1 (en) 2001-01-31 2001-11-13 Grayson Walker Stowell Form a of fluoxetine hydrochloride
US6313350B1 (en) 2001-01-31 2001-11-06 Grayson Walker Stowell Form a of fluoxetine hydrochloride
US6310250B1 (en) 2001-01-31 2001-10-30 Grayson Walker Stowell Form A of fluoxetine hydrochloride
US6310251B1 (en) 2001-01-31 2001-10-30 Grayson Walker Stowell Form a of fluoxetine hydrochloride
US6258853B1 (en) 2001-01-31 2001-07-10 Grayson Walker Stowell Form a of fluoxetine hydrochloride
US20070043100A1 (en) 2005-08-16 2007-02-22 Hagen Eric J Novel polymorphs of azabicyclohexane
US20080045725A1 (en) 2006-04-28 2008-02-21 Murry Jerry A Process For The Synthesis of (+) And (-)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane
EP2540725A1 (de) 2006-05-04 2013-01-02 Boehringer Ingelheim International GmbH Polymorphe von 1-((4-Methyl-chinazolin-2-yl)methyl)-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-amino-piperidin-1-yl)xanthin
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
PL2398468T3 (pl) 2009-02-17 2017-06-30 Krka, D.D., Novo Mesto Kompozycje farmaceutyczne zawierające zasadę prasugrelu lub jej farmaceutycznie dopuszczalne kwasowe sole addycyjne i sposoby ich otrzymywania
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
JP5952912B2 (ja) * 2011-12-15 2016-07-13 アルカーメス ファーマ アイルランド リミテッド 二級アミン化合物のプロドラッグ
JP6218811B2 (ja) 2012-05-14 2017-10-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
MX378004B (es) * 2015-12-02 2025-03-10 Jaime Samuel CHAIT AUERBACH Composición oral veterinaria con gabapentina.
CN109310697A (zh) 2016-06-10 2019-02-05 勃林格殷格翰国际有限公司 利格列汀和二甲双胍的组合
CN107334744B (zh) * 2017-07-24 2020-09-04 湖南洞庭药业股份有限公司 盐酸美金刚药物组合物和制法
CN107334742B (zh) * 2017-08-18 2020-01-31 山东力诺制药有限公司 一种盐酸氟西汀分散片及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4594358A (en) * 1985-02-25 1986-06-10 Eli Lilly And Company Analgesic method
CH678920A5 (no) * 1989-11-14 1991-11-29 Gergely Gerhard
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
EP0879048B2 (en) * 1996-02-09 2009-07-29 Quadrant Drug Delivery Limited Method for making tablets using trehalose
EP0792649A1 (en) * 1996-02-29 1997-09-03 Eli Lilly And Company Treatment of sleep disorders
CA2175939C (en) * 1996-05-07 1999-09-14 Michael Warnett Hetherington Manual capsule filling device
ES2227707T3 (es) * 1996-07-15 2005-04-01 Alza Corporation Nuevas formulaciones para la administracion transdermica de acetato de fluoxetina y de maleato de fluoxetina.
US5830500A (en) * 1996-07-22 1998-11-03 Pentech Pharmaceuticals, Inc. Low dose fluoxetine tablet

Also Published As

Publication number Publication date
WO1999049857A1 (en) 1999-10-07
AU3205399A (en) 1999-10-18
CN1303280A (zh) 2001-07-11
CA2325858A1 (en) 1999-10-07
ZA200005189B (en) 2001-05-22
BR9909118A (pt) 2001-10-16
KR20010034703A (ko) 2001-04-25
US20030013740A1 (en) 2003-01-16
EP1067918A1 (en) 2001-01-17
NO20004818D0 (no) 2000-09-26
JP2002509882A (ja) 2002-04-02

Similar Documents

Publication Publication Date Title
NO20004818L (no) Stabile doseringsformer av fluoxetin og dets enantiomere
EE200300212A (et) Ravimite kombinatsioonid (näiteks kloorpromasiin ja pentamidiin) neoplastiliste haiguste raviks
DK1023050T3 (da) Nye formuleringer af farmakologiske midler, fremgangsmåder til fremstillingen deraf og fremgangsmåder til anvendelsen deraf
ATE289640T1 (de) Amidofunktionelle aminopolydiorganosiloxane
IS6957A (is) Tatrat sölt af 5,8,14,-tríasatetrasýkló[10.3.1.02,11.04,9]-hexadeka-2(11),3,5,7,9,-pentaen og lyfjafræðilegar samsetningar af þeim
DK1787639T3 (da) Stabile farmaceutiske formuleringer til tryksamme dosisinhalatorer
DE60224284D1 (de) Stabile formulierung von modifiziertem glp-1
DE60032331D1 (de) Exendine zur glucagon suppression
ATE258928T1 (de) Respiratorisches syncytialvirus replikation inhibitoren
IS7076A (is) Bólusetning með einföldum skammti af Mycoplasma hyopneumoniae, og notkun efnisins í lækningaskyni
ATE259796T1 (de) Respiratorisches syncytialvirus replikation inhibitoren
MXPA03007712A (es) Sales farmaceuticas.
NZ526088A (en) Urea substituted imidazoquinoline ethers
BR0209580A (pt) Derivados de ciclohexan-1, 4 diamina substituìdos
NO20005224D0 (no) BTK inhibitorer og fremgangsmÕter for deres identifikasjon og anvendelse
PT1333887E (pt) Metodo de tratamento de desordens musculares
ITRM20020264A0 (it) Articolo assorbente e procedimento per la sua fabbricazione.
DK1417206T3 (da) Hidtil ukendte 2H-pyridazin-3-on-derivater, farmaceutiske præparater indeholdende det samme, og en fremgangsmåde til fremstilling af den aktive bestanddel
NO20006138D0 (no) Substituerte indolinoner, fremstilling og anvendelse derav som medikamenter
ATE231872T1 (de) Thiazolopyrimidinderivate
DK1097173T3 (da) Anvendelse af peptider af IL-2 og derivater deraf som terapeutiske midler
DK1185253T3 (da) Oralt præparat til indgivelse af en fast kombination af tramadol og diclofenac
DK1033990T3 (da) 21-Hydroxy-6,19-oxidoprogesteron (21OH-6OP) dets anvendelse som medikament i behandling af glucocorticoidoverskud
SE0101932D0 (sv) Pharmaceutical combinations
DK1957037T3 (da) Farmaceutisk præparat til nasal anvendelse af fentanyl